The TRMT1 (tRNA methyltransferase 1) antibody is a tool used to study the TRMT1 protein, an enzyme critical for post-transcriptional modification of transfer RNA (tRNA). TRMT1 catalyzes the methylation of tRNA molecules at the N2 position of guanine (m2G) at position 10 in the D-loop, a modification essential for tRNA stability, structural integrity, and proper function in translation. Dysregulation of TRMT1 has been linked to neurodevelopmental disorders, including intellectual disability and microcephaly, highlighting its role in cellular and neurological health. Antibodies targeting TRMT1 are typically developed in immunocompetent hosts (e.g., rabbits or mice) and validated for specificity through techniques like Western blotting, immunofluorescence, or immunoprecipitation. These antibodies enable researchers to investigate TRMT1 expression patterns, subcellular localization (primarily nuclear), and interactions in diverse biological contexts, including tRNA maturation pathways and disease mechanisms. Commercial TRMT1 antibodies often undergo quality controls using knockout cell lines to confirm target specificity. Their applications extend to both basic research and clinical studies, particularly in understanding tRNA epigenetics and molecular bases of TRMT1-associated disorders.